- In June 2020, CNS’s lead drug candidate, berubicin, received orphan drug designation from the FDA. In June 2021, it received Fast Track designation following positive results from an extensive clinical study which saw 44% of patients show clinical response, with a durable complete response
- With GBM having a survival rate of only 6.8% and an average survival time of only eight months, berubicin shows tremendous potential, and the CNS is leading the charge to find a potential treatment option for the disease.
- CNS management is optimistic about its lead drug candidate and continues to explore the potential treatment of other conditions such as lymphomas, lung and breast cancers
CNS Pharmaceuticals (NASDAQ: CNSP), a clinical-stage biotechnology company, recognizes the growing problem of metastatic cancers of the brain and central nervous system. More importantly, it recognizes how few and largely ineffective current solutions are, ultimately contributing to higher death rates and poor quality of life for victims with such conditions.
This understanding led to the introduction of berubicin, the company’s lead drug candidate to treat glioblastoma multiforme (“GBM”), with the potential to treat other central nervous system diseases as well.
NOTICE TO INVESTORS: The latest CNSP news and updates are available from the company newsroom at https://ibn.fm/CNSP
About BioMedWire
BioMedWire (BMW) is a biomedical news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries, and demographics in the most effective manner possible, (2) syndication of stories and articles to over 5,000 news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to millions of social media followers, (5) a full suite of corporate communications solutions, and (6) a comprehensive news coverage with BMW Premier. As a multi-faceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to better serve private and public companies wishing to reach a wide audience of investors, consumers, journalists and the general public. By reducing the information overload in today’s market, BMW provides customers with unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS alerts from BioMedWire, text “Biotech” to 844-397-5787 (US cell phones only)
For more information, please visit https://www.BioMedWire.com
Please review the full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever posted or republished: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]
BioMedWire is part of the InvestorBrandNetwork.
COMTEX_418886177/2801/2022-11-14T23:03:29
